A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia

Trial Profile

A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Idelalisib (Primary) ; Ofatumumab
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 16 May 2016 The protocol has been amened with the addition of the drug ofatumumab, accessing the safety and PK of idelalisib with or without ofatumumab.
    • 16 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Jun 2018.
    • 16 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top